IL124831A0 - Ob protein derivatives having prolonged half-life - Google Patents
Ob protein derivatives having prolonged half-lifeInfo
- Publication number
- IL124831A0 IL124831A0 IL12483196A IL12483196A IL124831A0 IL 124831 A0 IL124831 A0 IL 124831A0 IL 12483196 A IL12483196 A IL 12483196A IL 12483196 A IL12483196 A IL 12483196A IL 124831 A0 IL124831 A0 IL 124831A0
- Authority
- IL
- Israel
- Prior art keywords
- life
- derivatives
- protein derivatives
- protein
- prolonged half
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57949495A | 1995-12-27 | 1995-12-27 | |
US66718496A | 1996-06-20 | 1996-06-20 | |
PCT/US1996/020718 WO1997024440A1 (en) | 1995-12-27 | 1996-12-19 | Ob protein derivatives having prolonged half-life |
Publications (1)
Publication Number | Publication Date |
---|---|
IL124831A0 true IL124831A0 (en) | 1999-01-26 |
Family
ID=27077779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12483196A IL124831A0 (en) | 1995-12-27 | 1996-12-19 | Ob protein derivatives having prolonged half-life |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0870026B1 (xx) |
JP (1) | JP4037905B2 (xx) |
CN (1) | CN1154726C (xx) |
AT (1) | ATE267255T1 (xx) |
AU (1) | AU1520097A (xx) |
BR (1) | BR9612359A (xx) |
CA (1) | CA2238307A1 (xx) |
CZ (1) | CZ9802013A3 (xx) |
DE (1) | DE69632546T2 (xx) |
IL (1) | IL124831A0 (xx) |
MX (1) | MX9804687A (xx) |
NZ (1) | NZ326592A (xx) |
RU (1) | RU2178307C2 (xx) |
WO (1) | WO1997024440A1 (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
CA2358862A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
AU770897B2 (en) * | 1996-12-20 | 2004-03-04 | Amgen, Inc. | OB fusion protein compositions and methods |
PL194159B1 (pl) * | 1996-12-20 | 2007-05-31 | Amgen Inc | Proteina fuzyjna OB, kompozycja farmaceutyczna zawierająca tę proteinę i zastosowanie tej proteiny, a także kwas nukleinowy kodujący tę proteinę, wektor zawierający ten kwas nukleinowy, komórka gospodarza zawierająca ten wektor oraz sposób wytwarzania proteiny fuzyjnej OB |
AU2002300605B8 (en) * | 1997-04-17 | 2006-02-09 | Amgen Inc. | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods |
ES2183351T3 (es) * | 1997-04-17 | 2003-03-16 | Amgen Inc | Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. |
US6017876A (en) * | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
JP4380067B2 (ja) | 1998-04-23 | 2009-12-09 | 味の素株式会社 | 抗血栓活性物質及びグリコカリシンの検出法 |
US6492138B1 (en) | 1998-05-21 | 2002-12-10 | Amgen Canada Inc. | Polynucleotides encoding a novel SHC-binding protein |
US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
ES2286247T3 (es) * | 2001-02-21 | 2007-12-01 | Alavita Pharmaceuticals, Inc. | Proteinas anexinicas modificacdas y tratamiento de la trombosis. |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
NZ541365A (en) | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
EA011859B9 (ru) | 2004-01-05 | 2013-07-30 | Емд Лексиген Ресерч Сентер Корп. | Соединения для адресной доставки препарата к ткани или органу-мишени |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
EP2326339A4 (en) | 2008-05-21 | 2012-06-20 | Neurotez Inc | METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
CN104147596A (zh) * | 2013-05-14 | 2014-11-19 | 李荣秀 | 生物药非共价结合聚合物延长治疗浓度的方法及用途 |
CN104524568B (zh) * | 2015-01-08 | 2018-04-20 | 中国人民解放军第二军医大学 | 一种治疗肥胖症的药物组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
-
1996
- 1996-12-19 RU RU98113706/14A patent/RU2178307C2/ru active
- 1996-12-19 AT AT96945295T patent/ATE267255T1/de active
- 1996-12-19 DE DE69632546T patent/DE69632546T2/de not_active Expired - Lifetime
- 1996-12-19 IL IL12483196A patent/IL124831A0/xx unknown
- 1996-12-19 CN CNB961992654A patent/CN1154726C/zh not_active Expired - Lifetime
- 1996-12-19 NZ NZ326592A patent/NZ326592A/en not_active IP Right Cessation
- 1996-12-19 JP JP52455197A patent/JP4037905B2/ja not_active Expired - Lifetime
- 1996-12-19 EP EP96945295A patent/EP0870026B1/en not_active Expired - Lifetime
- 1996-12-19 WO PCT/US1996/020718 patent/WO1997024440A1/en active IP Right Grant
- 1996-12-19 CZ CZ982013A patent/CZ9802013A3/cs unknown
- 1996-12-19 AU AU15200/97A patent/AU1520097A/en not_active Abandoned
- 1996-12-19 BR BR9612359A patent/BR9612359A/pt not_active Application Discontinuation
- 1996-12-19 CA CA002238307A patent/CA2238307A1/en not_active Abandoned
-
1998
- 1998-06-11 MX MX9804687A patent/MX9804687A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ATE267255T1 (de) | 2004-06-15 |
CA2238307A1 (en) | 1997-07-10 |
DE69632546T2 (de) | 2005-06-30 |
NZ326592A (en) | 2001-05-25 |
MX9804687A (es) | 1998-10-31 |
JP4037905B2 (ja) | 2008-01-23 |
RU2178307C2 (ru) | 2002-01-20 |
DE69632546D1 (de) | 2004-06-24 |
WO1997024440A1 (en) | 1997-07-10 |
EP0870026A1 (en) | 1998-10-14 |
CZ9802013A3 (cs) | 1998-09-16 |
CN1154726C (zh) | 2004-06-23 |
AU1520097A (en) | 1997-07-28 |
EP0870026B1 (en) | 2004-05-19 |
CN1205738A (zh) | 1999-01-20 |
JP2000504210A (ja) | 2000-04-11 |
BR9612359A (pt) | 1999-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL124831A0 (en) | Ob protein derivatives having prolonged half-life | |
MX9602259A (es) | Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion. | |
PL341524A1 (en) | Novel receptor coupled wih g protein | |
DE69432109D1 (de) | Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung | |
BG103091A (en) | Shortened soluble receptors of type i & ii of the tumour necrotizing factor | |
NZ512083A (en) | Methods of increasing lean tissue mass using OB protein compositions | |
DK0877803T3 (da) | OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder | |
DK0601154T3 (da) | BPC-peptider, deres fremstilling og anvendelse | |
EP0754229A1 (en) | Alfamin: a human serum albumin-like protein | |
AU6921300A (en) | Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof | |
ATE346931T1 (de) | Clostridium perfringens impfstoff | |
AU3711597A (en) | A novel galanin receptor | |
WO1998016255A3 (en) | Stabilized conjugates of uncomplexed subunits of multimeric proteins | |
DE69734596D1 (de) | "smoothened" proteine aus wirbeltieren | |
DE59509948D1 (de) | Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein | |
NO992531L (no) | Fremgangsmåter ved fremstilling av rekombinant protein | |
SE9604439D0 (sv) | New receptor | |
NZ503256A (en) | Isolated proteins having retinol dehydrogenase activity, and which associate with retinol binding protein receptors | |
GB9604518D0 (en) | Novel compounds | |
AU7079300A (en) | Compositions and methods for the treatment of immune related diseases | |
EP0292302A3 (en) | Human splenin | |
MX9605048A (es) | Gonadotropinas con puentes de disulfuros no nativos. |